PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Phase III program in Chikungunya Fever.
Biotech’s 2024 IPO season kicks off with heavy demand for CG Oncology in $380M listing
NEW YORK — Bladder cancer drugmaker CG Oncology will debut on Nasdaq Thursday morning in what is expected to be the first of at least